Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent Chemotherapy and Hypofractionated RT for Inoperable NSCLC
NCT02619448Phase 1Recruiting
- Sponsor
- Upstate Medical University
- Start
- Dec 2014
- Primary completion
- Jul 2024
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of carboplatin and paclitaxel in non-small cell lung cancer (NSCLC), sponsored by Upstate Medical University. Primary endpoint: Toxicity as measured using CTCAE at 24 months. Started Dec 2014; status: recruiting.
02
Drugs
carboplatinpaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02619448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02619448.